Company news

Immutep Ltd news in 2023

Immutep Ltd's news releases, calls and decks from 2023, newest first.

View company

PEI provides constructive feedback for ph3 lung cancer trial

December 20, 2023

Immutep receives A$2.6 million French R&D Tax Incentive

December 6, 2023

Immutep Completes Enrolment for TACTI-003 Phase IIb Trial

November 8, 2023

Lead-in phase completed for ph2/3 trial in Breast Cancer

November 5, 2023

New Biomarker Data from TACTI-002 trial in 1st line NSCLC

November 2, 2023

Immutep reports promising data from INSIGHT-003 trial

October 23, 2023

Webcast slides for new Efti clinical data in 1st line NSCLC

October 22, 2023

Excellent Overall Survival in Non-Small Cell Lung Cancer

October 22, 2023

Immutep announces publication of ESMO 2023 abstracts

October 15, 2023

Commercial Scale Manufacturing of Efti for Clinical Trials

September 20, 2023

Appendix 4E & 2023 Full Year Statutory Accounts

August 29, 2023

Immutep receives positive scientific advice from EMA

August 1, 2023

1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial

July 27, 2023

US patent granted for Efti with PD-1 pathway inhibitor

June 27, 2023

Immutep granted US patent for IMP761 agonist LAG-3 antibody

June 20, 2023

A$80 million fully underwritten equity raising

May 30, 2023

Charles River Laboratories to run IMP761 Toxicology Study

May 28, 2023

Publication of Abstracts for ASCO 2023 Annual Meeting

May 25, 2023

1st patient dosed in AIPAC-003 ph2/3 breast cancer trial

May 24, 2023

Promising New Data in 1st line NSCLC from INSIGHT-003 Trial

May 23, 2023

Excellent initial Overall Survival Benefit in 1st line NSCLC

May 16, 2023

FDA supportive of Efti registrational trial in lung cancer

May 15, 2023

Approval to start Efti & Bavencio trial in urothelial cancer

April 30, 2023

Immutep to announce new TACTI-002 data at ASCO 2023

April 26, 2023

Response to ASX Aware Query

April 18, 2023

Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma

April 16, 2023

Positive Final Data in 2nd Line Metastatic NSCLC Patients

March 31, 2023

Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC

March 29, 2023

Initiation of Ph 2/3 Trial for Metastatic Breast Cancer

March 13, 2023

Enrolment Target Reached for INSIGHT-003 Trial in NSCLC

February 5, 2023

TACTI-003 trial 50% enrolment milestone has been achieved

January 3, 2023

Decks in 2023